This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Aegerion's Juxtapid Is Jumping

AEGR Chart AEGR data by YCharts

Updated with new information.

CAMBRIDGE, Mass. ( TheStreet) -- The commercial launch of Aegerion Pharmaceuticals' (AEGR - Get Report) Juxtapid continues to outperform investor expectations and the company raised sales guidance for the remainder of the year.

Aegerion said Tuesday that 215 patients are currently taking Juxtapid, which puts the company well on its way towards meeting the goal of having 250-300 patients on drug before the end of the year.

At the end of April, Aegerion reported 75 patients on Juxtapid therapy.

Aegerion shares are trading higher by 9 percent to $84.26. The stock reached an all-time high of $97.46 earlier in the day.

Juxtapid treats homozygous familial hypercholesterolemia (HoFH), a rare genetic disease that causes extremely high and potentially fatal levels of cholesterol to build up in patients' blood. A year of Juxtapid therapy costs $295,000.

Aegerion raised its Juxtapid sales forecast for 2013 to a range of $30-35 million from $15-25 million. The Street was already expecting Juxtapid sales of $31 million for the year, and that number is probably shooting higher in the coming days.

In addition to the 215 patients on Juxtapid already, Aegerion said 463 prescriptions have been written for the drug to date. This means 463 patients total have started the process of getting on Juxtapid therapy, including obtaining insurance reimbursement.

The company also said with six months of launch experience under its belt, the dropout rate from Juxtapid therapy is less than 10 percent and the compliance rate i.e. the percentage of patients who take their pill daily, is 80-90 percent.

"Aegerion's guidance is funny because I can get them doing $30 million in the fourth quarter alone," said one investor who is long the stock. "I can't believe Marc can keep a straight face."

"Marc" refers to Aegerion CEO Marc Beer, who this investor believes is sand-bagging the company's financial guidance in order to keep expectations reined in to a reasonable level.

For the second quarter, Aegerion reported a net loss of 66 cents per share on total revenue of $6.5 million.

Juxtapid competes against Kynamro, another drug for HoFH marketed by Sanofi (SNY - Get Report) and Isis Pharmaceuticals (ISIS).

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AEGR $2.34 0.86%
ISIS $34.01 -2.58%
SNY $38.95 -0.31%
AAPL $92.72 -0.56%
FB $119.49 1.43%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs